# KEROS THERAPEUTICS INC (KROS)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/KROS/

- Reporting holders: 3
- Reported value: $30.4K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $14.2K | 1,245 | 0.0% | 12 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $11.0K | 969 | 0.0% | 1 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $5.2K | 453 | 0.0% | 5 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 3 | $30.4K |
| Q2 2026 | 134 | $226.0M |
| Q1 2026 | 149 | $212.8M |
| Q4 2025 | 165 | $429.5M |
| Q3 2025 | 155 | $579.6M |
| Q2 2025 | 137 | $510.6M |
| Q1 2025 | 157 | $460.0M |
| Q4 2024 | 164 | $604.5M |
| Q3 2024 | 165 | $2.0B |
| Q2 2024 | 153 | $1.5B |
| Q1 2024 | 149 | $2.1B |
| Q4 2023 | 120 | $1.1B |